Your session is about to expire
← Back to Search
Device
Tumor Treating Fields for Lung Cancer
N/A
Waitlist Available
Led By John Waters, MD
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of stage I-IIIA NSCLC planned for surgical resection
Eastern Cooperative Oncology Group (ECOG) 0-2 performance status
Must not have
Pregnant or nursing patients due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants
Receipt of prior therapy for the current NSCLC
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 14-28 days
Awards & highlights
No Placebo-Only Group
Summary
"This trial aims to see how well TTFields work in treating early stage Non-Small Cell Lung Cancer in patients undergoing surgery. TTFields are a non-invasive treatment using low-intensity electrical fields to
Who is the study for?
This trial is for individuals with early-stage (I-IIIA) Non-Small Cell Lung Cancer who are candidates for surgery to remove the cancer. Participants should be able to undergo the TTFields treatment before their surgery.
What is being tested?
The study is testing the NovoTTF-200T System, a non-invasive device that delivers low-intensity electrical fields (TTFields) aimed at treating lung cancer by disrupting cancer cell division.
What are the potential side effects?
Potential side effects of using the NovoTTF-200T System may include skin irritation beneath the device pads, headaches, and malaise. However, since it's non-invasive, it tends to have fewer side effects than more aggressive treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My lung cancer is in an early stage and surgery is planned.
Select...
I am able to care for myself and up to being unable to work but can still move around.
Select...
I am 22 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am not pregnant or breastfeeding.
Select...
I have received treatment for my current lung cancer.
Select...
I do not have any serious illnesses that would stop me from following the study's requirements.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 14-28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 14-28 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Effect of TTF (Tumor-Treating Fields) on Fanconi anemia-related genes.
Secondary study objectives
Safety of administering TTFields
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Tumor Treatment FieldsExperimental Treatment1 Intervention
Duration: 2-4 week; target 18 hours/day (on average). Continuous between time of enrollment and date of surgery.
Cycle Length: 2-4 weeks
Find a Location
Who is running the clinical trial?
University of Texas Southwestern Medical CenterLead Sponsor
1,089 Previous Clinical Trials
1,059,665 Total Patients Enrolled
NovoCure Ltd.Industry Sponsor
63 Previous Clinical Trials
6,057 Total Patients Enrolled
John Waters, MDPrincipal InvestigatorUT Southwestern Medical Center